Contribute Try STAT+ Today

How a venture-backed startup gets its money is suddenly more fraught than it used to be.

As the Covid-19 pandemic effectively shuttered cities (and clinical trials), biotech executives looked for ways to keep their companies on track. Some took a hard look at their budgets Others shipped medications to the homes of enrolled clinical trial participants — and many, many people shared what they’ve learned. Some executives may be hoping that their venture capital investors will be flush enough to support them; for companies working on a Covid-related project, new funding sources may be an option.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.